Cargando…
原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态
OBJECTIVE: To test whether the tryptophan metabolism was abnormal in newly diagnosed ITP patients as well as in these patients after treatment with dexamethasone. METHODS: Newly diagnosed patients with ITP between Jan 2014 and May 2015 were enrolled, including 14 females and 11 males, with a median...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348388/ https://www.ncbi.nlm.nih.gov/pubmed/28395446 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.03.009 |
_version_ | 1783556812761464832 |
---|---|
collection | PubMed |
description | OBJECTIVE: To test whether the tryptophan metabolism was abnormal in newly diagnosed ITP patients as well as in these patients after treatment with dexamethasone. METHODS: Newly diagnosed patients with ITP between Jan 2014 and May 2015 were enrolled, including 14 females and 11 males, with a median age of 57 years and a median PLT count of 16 (0–32) ×10(9)/L. All patients were treated with oral dexamethasone. The expression levels of IDO mRNA and TTS mRNA in peripheral blood mononuclear cells (PBMC) were analyzed by real-time quantitative polymerase chain reaction. ELISA was used to test the concentrations of IDO and TTS in serum. The concentrations of plasma kynurenine and tryptophan were detected by high-pressure liquid chromatography. Samples from healthy individuals were tested as controls. RESULTS: ①After dexamethasone treatment, 17 patients resulted in persistent remission, 2 cases were ineffective, and relapse occurred in 6 cases at a median follow-up of 11 (6–18) months. ②Before and after dexamethasone treatment, the relative expression of indoleamine2,3-dioxygenase (IDO) mRNA and tryptophanyl t-RNA synthetase (TTS) mRNA showed that there were significant decline in persistent remission group (2.54±0.86 vs 19.85±5.36, t=3.188, P=0.003; 0.68±0.19 vs 45.39±15.83, t=2.842, P=0.008), compared with the normal control group, the difference was not statistically significant (t=2.313, P=0.027; t=1.127, P=0.268). After treatment, the IDO concentration decreased [(19.34±0.42) U/ml] and the TTS concentration was markedly increased [(13.37±0.54) µg/L] in sustained remission group compared with that before treatment [(21.91±0.37) U/ml] as well as that in normal controls. In particularly, abnormal tryptophan catabolism could be recovered in these 17 patients with persistent remission [Try: (19.85±5.36) µmol/L vs (19.65±4.55) µmol/L, t=1.027, P=0.311; Kyn: (0.56±0.26) µmol/L vs (0.58±0.23) µmol/L, t=2.075, P=0.448]. ③There was no obviously difference in the relative expression of IDO mRNA and TTS mRNA, the concentration of IDO and TTS and the abnormal tryptophan catabolism between before and after treatment of dexamethasone in patients without response and relapsed patients (all P>0.01). CONCLUSION: The tryptophan catabolism was abnormal in ITP patients, and it could be recovered in patients with persistent remission. |
format | Online Article Text |
id | pubmed-7348388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73483882020-07-16 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To test whether the tryptophan metabolism was abnormal in newly diagnosed ITP patients as well as in these patients after treatment with dexamethasone. METHODS: Newly diagnosed patients with ITP between Jan 2014 and May 2015 were enrolled, including 14 females and 11 males, with a median age of 57 years and a median PLT count of 16 (0–32) ×10(9)/L. All patients were treated with oral dexamethasone. The expression levels of IDO mRNA and TTS mRNA in peripheral blood mononuclear cells (PBMC) were analyzed by real-time quantitative polymerase chain reaction. ELISA was used to test the concentrations of IDO and TTS in serum. The concentrations of plasma kynurenine and tryptophan were detected by high-pressure liquid chromatography. Samples from healthy individuals were tested as controls. RESULTS: ①After dexamethasone treatment, 17 patients resulted in persistent remission, 2 cases were ineffective, and relapse occurred in 6 cases at a median follow-up of 11 (6–18) months. ②Before and after dexamethasone treatment, the relative expression of indoleamine2,3-dioxygenase (IDO) mRNA and tryptophanyl t-RNA synthetase (TTS) mRNA showed that there were significant decline in persistent remission group (2.54±0.86 vs 19.85±5.36, t=3.188, P=0.003; 0.68±0.19 vs 45.39±15.83, t=2.842, P=0.008), compared with the normal control group, the difference was not statistically significant (t=2.313, P=0.027; t=1.127, P=0.268). After treatment, the IDO concentration decreased [(19.34±0.42) U/ml] and the TTS concentration was markedly increased [(13.37±0.54) µg/L] in sustained remission group compared with that before treatment [(21.91±0.37) U/ml] as well as that in normal controls. In particularly, abnormal tryptophan catabolism could be recovered in these 17 patients with persistent remission [Try: (19.85±5.36) µmol/L vs (19.65±4.55) µmol/L, t=1.027, P=0.311; Kyn: (0.56±0.26) µmol/L vs (0.58±0.23) µmol/L, t=2.075, P=0.448]. ③There was no obviously difference in the relative expression of IDO mRNA and TTS mRNA, the concentration of IDO and TTS and the abnormal tryptophan catabolism between before and after treatment of dexamethasone in patients without response and relapsed patients (all P>0.01). CONCLUSION: The tryptophan catabolism was abnormal in ITP patients, and it could be recovered in patients with persistent remission. Editorial office of Chinese Journal of Hematology 2017-03 /pmc/articles/PMC7348388/ /pubmed/28395446 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.03.009 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 |
title | 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 |
title_full | 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 |
title_fullStr | 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 |
title_full_unstemmed | 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 |
title_short | 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 |
title_sort | 原发免疫性血小板减少症患者大剂量地塞米松治疗前后色氨酸代谢状态 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348388/ https://www.ncbi.nlm.nih.gov/pubmed/28395446 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.03.009 |
work_keys_str_mv | AT yuánfāmiǎnyìxìngxuèxiǎobǎnjiǎnshǎozhènghuànzhědàjìliàngdesāimǐsōngzhìliáoqiánhòusèānsuāndàixièzhuàngtài AT yuánfāmiǎnyìxìngxuèxiǎobǎnjiǎnshǎozhènghuànzhědàjìliàngdesāimǐsōngzhìliáoqiánhòusèānsuāndàixièzhuàngtài AT yuánfāmiǎnyìxìngxuèxiǎobǎnjiǎnshǎozhènghuànzhědàjìliàngdesāimǐsōngzhìliáoqiánhòusèānsuāndàixièzhuàngtài AT yuánfāmiǎnyìxìngxuèxiǎobǎnjiǎnshǎozhènghuànzhědàjìliàngdesāimǐsōngzhìliáoqiánhòusèānsuāndàixièzhuàngtài AT yuánfāmiǎnyìxìngxuèxiǎobǎnjiǎnshǎozhènghuànzhědàjìliàngdesāimǐsōngzhìliáoqiánhòusèānsuāndàixièzhuàngtài AT yuánfāmiǎnyìxìngxuèxiǎobǎnjiǎnshǎozhènghuànzhědàjìliàngdesāimǐsōngzhìliáoqiánhòusèānsuāndàixièzhuàngtài |